论文部分内容阅读
Objective:The aim of this study was to evaluate the efficacy and safety profile of DeFazio(S-1)combined with oxaliplatin against unresectable advanced or metastatic gastric cancer.Methods:Oxaliplatin was given intravenously at 130mg/m2for 2 h on d1 and S-1 was administered bid.at 80 mg/m2/day on d1–14 followed by a 7-day rest during the 3-week schedule.Results:All 62 patients were assessed for efficacy and adverse events.The response and disease control rates were 47.3%and 80.8%,respectively.The median time to progression was 7.8 months,and the median overall survival was11.6 months.The grade 3/4 adverse events were hematological toxicities,including neutropenia(11.3%),thrombocytopenia(9.7%)and gastrointestinal reactions(6.5%).Conclusion:The SOX regimen(oxaliplatin,130 mg/m2d1;S-1,80 mg/m2/day,bid.d1-14,q3w)provide a favorable efficacy and safety profile in patients with advanced gastric cancer.
Objective: The aim of this study was to evaluate the efficacy and safety profile of DeFazio (S-1) combined with oxaliplatin against unresectable advanced or metastatic gastric cancer. Methods: Oxaliplatin was given intravenously at 130 mg / m2 for 2 h on d1 and S- 1 was administered bid. At 80 mg / m2 / day on d1-14 followed by a 7-day rest during the 3-week schedule. Results: All 62 patients were assessed for efficacy and adverse events. Response and disease control rates were 47.3% and 80.8%, respectively. The median time to progression was 7.8 months, and the median overall survival was 11.6 months. The grade 3/4 adverse events were hematological toxicities, including neutropenia (11.3%), thrombocytopenia (9.7% Conclusion: The SOX regimen (oxaliplatin, 130 mg / m2d1; S-1,80 mg / m2 / day, bid.d1-14, q3w) provides a favorable efficacy and safety profile in patients with advanced gastric cancer.